Retatrutide

An investigational triple agonist still in clinical trials, not approved anywhere.

What it is

Retatrutide acts on three receptors: GLP-1, GIP, and glucagon. It is an experimental compound in ongoing phase 3 trials.

How it works

The first two receptors work much like tirzepatide. Adding glucagon activity raises energy expenditure, which is the main difference in the published mechanism.

What it is researched for

• Weight reduction in trial settings
• Metabolic and liver fat endpoints

Research status

Investigational. Not approved for human use in any country. Long-term safety is unknown.

What to watch for

• Heart rate increases reported in trials
• Strong digestive side effects at higher doses
• No approved supply chain, so material quality is unverifiable

Storage

Lyophilised powder keeps in the freezer or fridge, away from light. Once reconstituted with bacteriostatic water, keep it refrigerated and use it within about four weeks.

Common questions

Why is there so little dosing detail here?

Retatrutide is unapproved and still in trials. We report the mechanism and the research status and leave dosing specifics out on purpose.

When might it be approved?

Phase 3 results are still reading out. Any approval date would be speculation.

Educational reference only, not medical advice.